All News CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

Delayed Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.204 ^USD	-0.20%		-15.00%	-83.94%

Apr. 01	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 27	CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CNS Pharmaceuticals to Present at Two Investor Conferences in April	Apr. 02	AQ
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	Feb. 27	CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	Jan. 30	MT
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	Jan. 30	AQ
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	Jan. 30	MT
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	Jan. 19	AQ
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	Jan. 18	CI
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 18	AQ
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	Jan. 17	CI
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	Dec. 18	PU
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	Dec. 18	CI
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	Dec. 07	AQ
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	Nov. 22	CI
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	Nov. 17	AQ
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	Nov. 16	AQ
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	Nov. 15	PU
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference	23-10-20	AQ
CNS Pharmaceuticals : Regulation FD Disclosure - Form 8-K	23-10-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H2013

All News

Filters